Having migraines does not lead to brain damage with age

October 17, 2024

If you’re one of the millions of people who suffer from migraines, you might be worried about the long-term effects on your brain. Recent studies have suggested that people with migraines might be at higher risk for structural brain changes, such as damage to small vessels in the brain and shrinkage of the brain or brain atrophy.

A recent study published in Cephalalgia by Dutch researchers examined the connection between migraines and brain health in over 4,900 middle-aged and elderly people. The researchers used magnetic resonance imaging (MRI) to study the brains of the participants and assess any structural changes.

The study found that people with migraines were not any more likely to have structural brain changes than those without migraines. There were no significant differences between the two groups in terms of:

  • Total brain volume
  • Grey matter volume
  • White matter volume
  • White matter hyperintensity volume (a marker for small vessel disease)
  • Presence of lacunes (tiny holes in the brain)
  • Presence of cerebral microbleeds (small bleeds in the brain)

This study suggests that having migraines may not increase your risk of developing structural brain changes as you age. This is reassuring news for people who suffer from migraines and are concerned about the long-term effects on their brain health.

Written by
Alexander Mauskop, MD
Continue reading
August 8, 2026
Sugar is bad for your brain, even before you are born.
Sugar consumed in the first two years of life increases the risk of dementia.
Read article
August 6, 2026
Research
An Old Medicine that Could Make Brain Stimulation Work Better for Depression and Other Neurological Conditions
A 2022 clinical trial from the University of Calgary found that adding low‑dose D‑cycloserine (DCS), a partial NMDA‑receptor agonist, to intermittent theta‑burst stimulation (iTBS) significantly increased response and remission rates in depression without serious side effects. Early follow‑up data suggest that timing, dose, and drug levels matter, and raise the possibility that this DCS‑TMS approach could eventually be applied to other neurological conditions—such as migraine, postconcussion syndrome, brain fog, and long COVID
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe